| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... Cancer discovery 3 (12), 1416-1429, 2013 | 451* | 2013 |
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014 | 330 | 2014 |
| Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation T Pemovska, E Johnson, M Kontro, GA Repasky, J Chen, P Wells, ... Nature 519 (7541), 102-105, 2015 | 269 | 2015 |
| Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions P Valent, A Orazi, MR Savona, MM Patnaik, F Onida, ... haematologica 104 (10), 1935, 2019 | 132 | 2019 |
| Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, EI Andersson, ... Leukemia 28 (8), 1738-1742, 2014 | 131 | 2014 |
| JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ... Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017 | 126 | 2017 |
| Recent advances in combinatorial drug screening and synergy scoring T Pemovska, JW Bigenzahn, G Superti-Furga Current opinion in pharmacology 42, 102-110, 2018 | 111 | 2018 |
| Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders C Kornauth, T Pemovska, GI Vladimer, G Bayer, M Bergmann, S Eder, ... Cancer discovery, candisc. 0538.2021, 2021 | 103 | 2021 |
| HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ... Leukemia 31 (2), 301-309, 2017 | 94 | 2017 |
| Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ... Leukemia 32 (3), 774-787, 2018 | 91 | 2018 |
| Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia S Eldfors, H Kuusanmäki, M Kontro, MM Majumder, A Parsons, H Edgren, ... Leukemia 31 (1), 51-57, 2017 | 57 | 2017 |
| Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ... Leukemia 31 (5), 1187-1195, 2017 | 55 | 2017 |
| Development of metastatic HER2+ breast cancer is independent of the adaptive immune system M Ciampricotti, K Vrijland, CS Hau, T Pemovska, CW Doornebal, ... The Journal of pathology 224 (1), 56-66, 2011 | 42 | 2011 |
| Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL C Schmidl, GI Vladimer, AF Rendeiro, S Schnabl, T Krausgruber, ... Nature chemical biology 15 (3), 232-240, 2019 | 41 | 2019 |
| Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing PO Pietarinen, T Pemovska, M Kontro, B Yadav, JP Mpindi, EI Andersson, ... Blood cancer journal 5 (5), e309-e309, 2015 | 35 | 2015 |
| From drug response profiling to target addiction scoring in cancer cell models B Yadav, P Gopalacharyulu, T Pemovska, SA Khan, A Szwajda, J Tang, ... Disease models & mechanisms 8 (10), 1255-1264, 2015 | 21 | 2015 |
| Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors PO Pietarinen, CA Eide, P Ayuda-Durán, S Potdar, H Kuusanmäki, ... Oncotarget 8 (14), 22606, 2017 | 20 | 2017 |
| Core-binding factor leukemia hijacks the T-cell–prone PU. 1 antisense promoter E van der Kouwe, G Heller, A Czibere, JA Pulikkan, C Agreiter, ... Blood, The Journal of the American Society of Hematology 138 (15), 1345-1358, 2021 | 16 | 2021 |
| 8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia R Buettner, LXT Nguyen, B Kumar, C Morales, C Liu, LS Chen, ... Journal of cellular physiology 234 (9), 16295-16303, 2019 | 16 | 2019 |
| Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine T Heinemann, C Kornauth, Y Severin, GI Vladimer, T Pemovska, ... Blood Cancer Discovery 3 (6), 502-515, 2022 | 13 | 2022 |
